GBT 009

Drug Profile

GBT 009

Alternative Names: GBT009

Latest Information Update: 12 Sep 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Garnet BioTherapeutics
  • Class Cell therapies
  • Mechanism of Action Cytokine stimulants; Intercellular signalling peptide and protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Scars

Most Recent Events

  • 12 Sep 2015 No recent reports of development identified - Phase-II for Scars (Prevention) in USA (Intradermal)
  • 28 Jan 2015 Garnet BioTherapeutics filed a friend of the court (amicus) brief at the Federal Circuit to protect its rights against Athersys in a patent interference
  • 26 Sep 2014 Garnet BioTherapeutics receives patent allowance for Cell Populations Which Co-Express CD49c and CD90 in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top